Market Overview

Valeant Pharma Announces Medicis Five-Year Aesthetic Collaboration with Mentor

Share:
Related VRX
Morgan Stanley Lifts Target On Valeant From $235 To $284
Stocks Hitting 52-Week Highs
Amgen Stock Hits High As Street Eyes Growth Drivers (Investor's Business Daily)

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that Valeant's Medicis division, a leader in facial injectables and professional skin care, has formed a collaboration with Mentor Worldwide LLC, the U.S. market leader in breast aesthetics, to enter certain of their non-reimbursed products into a combined physician loyalty program. The new program, called the M^2VP (Medicis-Mentor Valued Partner) program, extends the offerings of Medicis' recently-launched MVP program to include the MENTOR^® line of breast implant products for a five-year term and is for the U.S., subject to any geographical expansion that may be agreed upon by the parties.

The M^2VP program offers numerous incentives that reward utilization of various products across the Mentor and Medicis portfolios. Unlike other programs in the space, the M^2VP program allows participating members to not only earn points that establish status within the program, but to redeem them for items such as product purchases. In designing the program, Mentor and Medicis sought to address many of the issues that customers felt existed with other programs.

Posted-In: News

 

Related Articles (VRX)

Get Benzinga's Newsletters